Janakiraman Subramanian
YOU?
Author Swipe
Immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in lung cancer: a case series Open
Immune checkpoint inhibitors (ICIs) are established treatments for various malignancies, including lung, kidney, and colorectal cancers. However, their broad use has led to an increase in immune-related adverse events (irAEs), with thyroid…
Prevalence of anxiety disorder among undergraduate medical students: a cross-sectional study Open
Background: It is widely acknowledged that medical colleges are stressful places that frequently have a detrimental impact on students academic performance, physical, mental health and psychological well-being. Depression, anxiety, stress,…
APPLICATION OF FILM SPRAY TECHNOLOGY FOR THE ENHANCEMENT OF TRANSDERMAL DRUG DELIVERY SYSTEM- A REVIEW Open
Conventional topical preparations hold wider utility for various purposes and therapies, yet holds few drawbacks including irritability, lower bio-availability of actives in sites, along with poor local and systemic effects. In current top…
Long-Term Survival by Number of Immune Checkpoint Inhibitors in PD-L1–Negative Metastatic NSCLC Open
This systematic review and meta-analysis evaluates long-term survival outcomes by number of immune checkpoint inhibitors among patients with programmed death-ligand 1 (PD-L1)–negative non–small cell lung cancer (NSCLC).
State of Lung Cancer in Egypt: Moving Towards Improved Guidelines for Prevention, Screening, Treatment, and Clinical Care Programs Open
Lung cancer remains a leading cause of cancer-related mortality globally and presents significant challenges in Egypt. In 2023, the first annual meeting of the Thoracic Oncology Multidisciplinary Faculty, organized by the Egyptian Cancer R…
View article: Cost of early progression: patients with epidermal growth factor receptor mutated metastatic non-small-cell lung cancer
Cost of early progression: patients with epidermal growth factor receptor mutated metastatic non-small-cell lung cancer Open
Aim: Compare healthcare costs for patients with epidermal growth factor receptor mutated (EGFRm) metastatic non-small-cell lung cancer (mNSCLC) with and without progression and estimate costs of progression.Materials & methods: Retrospecti…
Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non–Small-Cell Lung Cancer Open
Adding PROphet to PD-L1 expression impacted therapeutic decision making in first-line NSCLC. PROphet identifies those predicted to have an overall survival benefit from ICI monotherapy versus combination versus chemotherapy, improving the …
Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors Open
Immune-related adverse events (irAEs) are the most common complication of immune checkpoint inhibitor (ICI) therapy. With the widespread use of ICIs in patients with solid tumors, up to 40% of the patients develop irAEs within five months …
Exceptional synergistic response of PARP inhibitor and immune checkpoint inhibitor in esophageal adenocarcinoma with a germline BRCA2 mutation: a case report Open
Immune checkpoint inhibitors (ICIs) and poly (ADP-ribose) polymerase (PARP) inhibitors have shown efficacy in various tumors. A significant therapeutic challenge with either ICIs or PARP inhibitors as monotherapy is treatment failure from …
Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting Open
Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive disease with poor 5-year survival. The first-line standard-of-care for ES-SCLC is platinum plus etoposide, along with 1 of the immune checkpoint inhibitors atezolizumab or d…
Molecular Tumor Board Case Series: Targeting KRAS G12C in Lung Cancer. Open
Next-generation sequencing (NGS) identifies biomarkers with prognostic and predictive importance in patients with cancer. The enormous amounts of data generated by comprehensive NGS adds complexity to the identification of valid drug thera…
532 A cross-cohort examination of factors impacting immunotherapy survival in non-small cell lung cancer (NSCLC) Open
Background Highly variable responses to immune checkpoint inhibitors (ICI) among NSCLC patients underscore the need for predictive biomarkers to guide therapy selection. In this study, RNA-seq data were used to classify patients into our p…
View article: Treatment Patterns and Adverse Event-Related Hospitalization Among Patients with Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non-small Cell Lung Cancer After Treatment with EGFR Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy Regimens
Treatment Patterns and Adverse Event-Related Hospitalization Among Patients with Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non-small Cell Lung Cancer After Treatment with EGFR Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy Regimens Open
Among EGFR TKI-resistant patients who discontinued platinum-based chemotherapy, the duration of the next line of therapy was short, treatment was highly variable, and re-treatment with EGFR TKIs and platinum-based regimens was common, sugg…
Large‐scale pathogenicity prediction analysis of cancer‐associated kinase mutations reveals variability in sensitivity and specificity of computational methods Open
Background Mutations in kinases are the most frequent genetic alterations in cancer; however, experimental evidence establishing their cancerous nature is available only for a small fraction of these mutants. Aims Predicition analysis of k…
Molecular Tumor Board Case Series: Targeted Treatments For Cancer And Their Toxicities: Amivantamab-Induced Linear IgA Bullous Dermatosis. Open
In the era of targeted treatments based on next generation sequencing (NGS) analysis, clinicians must be diligent in aligning patients with treatments giving them the best chance of survival while weighing the risk of toxicity caused by ag…
Supplementary file containing supplementary Table 1, 2, 3 and Supplementary Figure 1a,1b,1c and 1d. from Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers Open
Supplementary Table 1. Common genes between Caris, Paradigm and Guardant360 platforms Supplementary Table 2: Common mutations between Guardant 360 and Caris/Paradigm platforms Supplementary Table 3: Actionable mutations detected both in ti…
View article: Supplementary file containing supplementary Table 1, 2, 3 and Supplementary Figure 1a,1b,1c and 1d. from Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers
Supplementary file containing supplementary Table 1, 2, 3 and Supplementary Figure 1a,1b,1c and 1d. from Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers Open
Supplementary Table 1. Common genes between Caris, Paradigm and Guardant360 platforms Supplementary Table 2: Common mutations between Guardant 360 and Caris/Paradigm platforms Supplementary Table 3: Actionable mutations detected both in ti…